RxDoctor Payments Data

Catherine Hartjoy, PA

Physician Assistant · Tacoma, WANPI 1275520066

Payments from drug & device makers

$4,386in general payments, 2019–2025

Across 208 payments — averaging $21.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$678
  • AbbVie$676
  • Boehringer Ingelheim$466
  • AstraZeneca$338
  • Novo Nordisk$303
  • Astellas Pharma US Inc$235
  • plus $2K from 26 others

What the payments were for

  • Food & beverage$4,28098%
  • Education$1072%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,386 in reported general payments places this provider in the 95th percentile of 2,741 physician assistant providers in Washington.

See all physician assistant providers in Washington

Medicare billing

Part B allowed, 2024
$31,936
Medicare patients
115
Services billed
520

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin54$40,749
OzempicSemaglutide31$35,103
XareltoRivaroxaban25$25,880
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$18,365
EliquisApixaban22$17,117
FarxigaDapagliflozin Propanediol15$11,726
Bydureon BciseExenatide Microspheres12$9,270
Spiriva RespimatTiotropium Bromide12$7,361
GemtesaVibegron11$7,257
Xigduo XrDapaglifloz Propaned/Metformin12$7,080
Lantus SolostarInsulin Glargine,hum.Rec.Anlog39$4,589
Omeprazole88$1,703
Atorvastatin Calcium134$1,378
Colestipol Hcl13$1,337
Losartan Potassium146$1,272

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Spiriva Respimat$466$48,11066 claims
Novo NordiskOzempic$303$35,10331 claims
Johnson & JohnsonXarelto$93$25,88025 claims
GSKTrelegy Ellipta$208$18,36528 claims
PfizerEliquis$189$17,11722 claims
AstraZenecaFarxiga$338$11,72615 claims
Sumitomo Pharma America, Inc.Gemtesa$46$7,25711 claims
AbbVieSynthroid$676$1,04813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,741 physician assistant providers in Washington.

Other physician assistant in Tacoma

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →